Validation of Biomarkers Predictive of Recurrence Following Prostatectomy
Abstract
Thus far we have made good progress on our goal to validate biomarkers of recurrence in prostate cancer. We have published a manuscript now in press at The American Journal of Pathology describing our set of biomarkers, and will be presenting these data orally at the American Society of Investigative Pathology annual meeting in Washington, DC on April 11, 2011. We have initiated collection of samples at the Atlanta VA Medical Center and begun tissue coring and RNA extraction. We have faced some administrative hurdles with getting the project started regarding IRB approvals and subcontract awards. However, now that all of these obstacles have been overcome, we expect rapid progress in the next year for data generation. In addition, the miRNA DASL platform has been discontinued by Illumina, and we are thus planning on transitioning the project to next generation sequencing methods, which are likely to be more accurate and comprehensive. Because of the delays in getting the project initiated, we are requesting a no cost one year extension to change the project from at two-year to a three-year project.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 14, 2011
- Accession Number
- ADA543731
Entities
People
- Carlos S Moreno
Organizations
- Emory University